Peptide therapeutics in neurodegenerative disorders

Current Medicinal Chemistry

Volumn 21, Issue 23, 2014, Pages 2610-2631

  Tiwari, Shashi Kant ^a,b   Chaturvedi, Rajnish K ^a,b  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Mitochondrial dysfunction; Neurodegenerative diseases; Neuropeptide; Neurotrophin; Parkinson's disease

Indexed keywords

ADRENOMEDULLIN; AMBP1 PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; BRAIN DERIVED NEUROTROPHIC FACTOR; CEREBROLYSIN; CILIARY NEUROTROPHIC FACTOR; COLIVELIN; CORTICOTROPIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HUMANIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE 2; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTROPHIN 3; NEUROTROPHIN 3 RECEPTOR; NEUROTROPHIN 4; NEUROTROPIN; NEURTURIN; PROTEIN KINASE B; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN B; SOMATOMEDIN C; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; PEPTIDE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTICLE; BETA SHEET; BLOOD BRAIN BARRIER; CELL PROLIFERATION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DISEASE COURSE; GLIA CELL; HUMAN; HUNTINGTON CHOREA; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM; MITOCHONDRION; NEURODEGENERATIVE DISEASES; PROTEIN SECONDARY STRUCTURE;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; SIGNAL TRANSDUCTION;

EID: 84903733042     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140217125857     Document Type: Article

References (307)

1. Moskowitz, M.A. Brain protection: maybe yes, maybe no. Stroke, 2010, 41 (10 Suppl), S85-86.
2. Chaturvedi, R.K.; Flint Beal, M. Mitochondrial Diseases of the Brain. Free Radical. Bio.Med., 2013, 63C, 1-29.
3. Portera-Cailliau, C.; Hedreen, J.C.; Price, D.L.; Koliatsos, V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci., 1995, 15 (5 Pt 2), 3775-3787.
4. Loo, D.T.; Copani, A.; Pike, C.J.; Whittemore, E.R.; Walencewicz, A.J.; Cotman, C.W. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci., U S A, 1993, 90 (17), 7951-7955.
5. Rabizadeh, S.; Gralla, E.B.; Borchelt, D.R.; Gwinn, R.; Valentine, J.S.; Sisodia, S.; Wong, P.; Lee, M.; Hahn, H.; Bredesen, D.E. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc. Natl. Acad. Sci. U S A, 1995, 92 (7), 3024-3028.
6. Lunn, J.S.; Sakowski, S.A.; Federici, T.; Glass, J.D.; Boulis, N.M.; Feldman, E.L. Stem cell technology for the study and treatment of motor neuron diseases. Regen. Med., 2011, 6 (2), 201-213.
7. Park, H.; Poo, M.M. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci, 2013, 14 (1), 7-23.
8. Trang, T.; Beggs, S.; Salter, M.W. Brain-derived neurotrophic factor from microglia: a molecular substrate for neuropathic pain. Neuron Glia Biol., 2011, 7 (1), 99-108.
9. McKelvey, L.; Shorten, G.D.; O'Keeffe, G.W. Nerve growth factormediated regulation of pain signalling and proposed new interven tion strategies in clinical pain management. J. Neurochem., 2013, 124 (3), 276-289.
10. Chaturvedi, R.K.; Shukla, S.; Seth, K.; Agrawal, A.K. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease. Neurosci. Lett., 2006, 398 (1-2), 44-49.
11. Chaturvedi, R.K.; Agrawal, A.K.; Seth, K.; Shukla, S.; Chauhan, S.; Shukla, Y.; Sinha, C.; Seth, P.K. Effect of glial cell line-derived neurotrophic factor (GDNF) co-transplantation with fetal ventral mesencephalic cells (VMC) on functional restoration in 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson's disease: neurobehavioral, neurochemical and immunohistochemical studies. Int. J. Dev. Neurosci., 2003, 21 (7), 391-400.
12. Allen, S.J.; Watson, J.J.; Shoemark, D.K.; Barua, N.U.; Patel, N.K. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther., 2013, 138 (2), 155-175.
13. Lu, B.; Pang, P.T.; Woo, N.H. The yin and yang of neurotrophin action. Nat. Rev. Neurosci., 2005, 6 (8), 603-614.
14. Perovic, M.; Tesic, V.; Mladenovic Djordjevic, A.; Smiljanic, K.; Loncarevic-Vasiljkovic, N.; Ruzdijic, S.; Kanazir, S. BDNF transcripts, proBDNF and proNGF, in the cortex and hippocampus throughout the life span of the rat. Age (Dordr), 2013, 35(8), 2057-2070
15. Allen, S.J.; Watson, J.J.; Dawbarn, D. The neurotrophins and their role in Alzheimer's disease. Curr. Neuropharmacol., 2011, 9 (4), 559-573.
16. Weishaupt, N.; Blesch, A.; Fouad, K. BDNF: the career of a multifaceted neurotrophin in spinal cord injury. Exp. Neurol., 2012, 238 (2), 254-264.
17. Ruozi, B.; Belletti, D.; Bondioli, L.; De Vita, A.; Forni, F.; Vandelli, M.A.; Tosi, G. Neurotrophic factors and neurodegenerative diseases: a delivery issue. Int. Rev. Neurobiol., 2012, 102, 207-247.
18. Salinas, M.; Diaz, R.; Abraham, N.G.; Ruiz de Galarreta, C.M.; Cuadrado, A. Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinasedependent manner. J. Biol. Chem., 2003, 278 (16), 13898-13904.
19. Shimoke, K.; Chiba, H. Nerve growth factor prevents 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease. J. Neurosci. Res., 2001, 63 (5), 402-409.
20. Weidner, N.; Blesch, A.; Grill, R.J.; Tuszynski, M.H. Nerve growth factor-hypersecreting Schwann cell grafts augment and guide spinal cord axonal growth and remyelinate central nervous system axons in a phenotypically appropriate manner that correlates with expression of L1. J. Comp. Neurol., 1999, 413 (4), 495-506.
21. Lorigados Pedre, L.; Pavon Fuentes, N.; Alvarez Gonzalez, L.; McRae, A.; Serrano Sanchez, T.; Blanco Lescano, L.; Macias Gonzalez, R. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res., 2002, 952 (1), 122-127.
22. Elliott, E.; Atlas, R.; Lange, A.; Ginzburg, I. Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 Kinase signalling mechanism. Eur. J. Neurosci., 2005, 22 (5), 1081-1089.
23. Elliott, E.; Ginzburg, I. The role of neurotrophins and insulin on tau pathology in Alzheimer's disease. Rev. Neurosci., 2006, 17 (6), 635-642.
24. Cattaneo, A.; Calissano, P. Nerve growth factor and Alzheimer's disease: new facts for an old hypothesis. Mol. Neurobiol., 2012, 46 (3), 588-604.
25. Chae, C.H.; Lee, H.C.; Jung, S.L.; Kim, T.W.; Kim, J.H.; Kim, N.J.; Kim, H.T. Swimming exercise increases the level of nerve growth factor and stimulates neurogenesis in adult rat hippocampus. Neuroscience., 2012, 212, 30-37.
26. Birch, A.M.; McGarry, N.B.; Kelly, A.M. Short-term environmental enrichment, in the absence of exercise, improves memory, and increases NGF concentration, early neuronal survival, and synaptogenesis in the dentate gyrus in a time-dependent manner. Hippocampus, 2013, 23 (6), 437-450.
27. Frielingsdorf, H.; Simpson, D.R.; Thal, L.J.; Pizzo, D.P. Nerve growth factor promotes survival of new neurons in the adult hippocampus. Neurobiol Dis., 2007, 26 (1), 47-55.
28. Zhu, W.; Cheng, S.; Xu, G.; Ma, M.; Zhou, Z.; Liu, D.; Liu, X. Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia. Drug Deliv., 2011, 18 (5), 338-343.
29. Pandya, C.D.; Kutiyanawalla, A.; Pillai, A. BDNF-TrkB signaling and neuroprotection in schizophrenia. Asian J Psychiatr., 2013, 6 (1), 22-28.
30. Lu, B.; Nagappan, G.; Guan, X.; Nathan, P.J.; Wren, P. BDNFbased synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature Rev., 2013, 14 (6), 401-416.
31. Neto, F.L.; Borges, G.; Torres-Sanchez, S.; Mico, J.A.; Berrocoso, E. Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr. Neuropharmacol., 2011, 9 (4), 530-552.
32. Chen, B.Y.; Wang, X.; Wang, Z.Y.; Wang, Y.Z.; Chen, L.W.; Luo, Z.J. Brain-derived neurotrophic factor stimulates proliferation and differentiation of neural stem cells, possibly by triggering the Wnt/beta-catenin signaling pathway. J. Neurosci. Res., 2013, 91 (1), 30-41.
33. Oliveira, S.L.; Pillat, M.M.; Cheffer, A.; Lameu, C.; Schwindt, T.T.; Ulrich, H. Functions of neurotrophins and growth factors in neurogenesis and brain repair. Cytometry A, 2013, 83 (1), 76-89.
34. Boiocchi, C.; Maggioli, E.; Zorzetto, M.; Sinforiani, E.; Cereda, C.; Ricevuti, G.; Cuccia, M. Brain-derived neurotrophic factor gene (BDNF) variants and Alzheimer's disease: an association study in an AD Italian population. Rejuvenation Res., 2013, 16, 57-66.
35. Real, C.C.; Ferreira, A.F.; Chaves-Kirsten, G.P.; Torrao, A.S.; Pires, R.S.; Britto, L.R. BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson s disease. Neuroscience., 2013, 1(237), 118-29.
36. Hu, Y.; Russek, S.J. BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. J. Neurochem., 2008, 105 (1), 1-17.
37. Ciammola, A.; Sassone, J.; Cannella, M.; Calza, S.; Poletti, B.; Frati, L.; Squitieri, F.; Silani, V. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. Am J Med Genet B Neuropsychiatr Genet., 2007, 144B (4), 574-577.
38. O'Bryant, S.E.; Hobson, V.L.; Hall, J.R.; Barber, R.C.; Zhang, S.; Johnson, L.; Diaz-Arrastia, R. Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement. Geriatr. Cogn. Disord., 2011, 31 (1), 31-36.
39. Peng, S.; Garzon, D.J.; Marchese, M.; Klein, W.; Ginsberg, S.D.; Francis, B.M.; Mount, H.T.; Mufson, E.J.; Salehi, A.; Fahnestock, M. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J. Neurosci., 2009, 29 (29), 9321-9329.
40. Conforti, P.; Ramos, C.; Apostol, B.L.; Simmons, D.A.; Nguyen, H.P.; Riess, O.; Thompson, L.M.; Zuccato, C.; Cattaneo, E. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol. Cell. Neurosci., 2008, 39 (1), 1-7.
41. Zuccato, C.; Cattaneo, E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol., 2007, 81 (5-6), 294-330.
42. Canals, J.M.; Pineda, J.R.; Torres-Peraza, J.F.; Bosch, M.; Martin-Ibanez, R.; Munoz, M.T.; Mengod, G.; Ernfors, P.; Alberch, J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci., 2004, 24 (35), 7727-7739.
43. Bemelmans, A.P.; Horellou, P.; Pradier, L.; Brunet, I.; Colin, P.; Mallet, J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther., 1999, 10 (18), 2987-2997.
44. Cho, S.R.; Benraiss, A.; Chmielnicki, E.; Samdani, A.; Economides, A.; Goldman, S.A. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J. Clin. Invest., 2007, 117 (10), 2889-2902.
45. Benraiss, A.; Toner, M.J.; Xu, Q.; Bruel-Jungerman, E.; Rogers, E.H.; Wang, F.; Economides, A.N.; Davidson, B.L.; Kageyama, R.; Nedergaard, M.; Goldman, S.A. Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease. Cell stem cell., 2013, 12 (6), 787-799.
46. Li, Q.S.; Yang, W.; Pan, Y.F.; Min, J.; Zhang, Z.; Gao, H.Z.; Qi, J.S. [Brain-derived neurotrophic factor prevents against amyloid beta protein-induced impairment of hippocampal in vivo long-term potentiation in rats]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chin. J. App. Physiol., 2012, 28 (5), 425-429.
47. Agrawal, A.K.; Shukla, S.; Chaturvedi, R.K.; Seth, K.; Srivastava, N.; Ahmad, A.; Seth, P.K. Olfactory ensheathing cell transplantation restores functional deficits in rat model of Parkinson's disease: a cotransplantation approach with fetal ventral mesencephalic cells. Neurobiol. Dis., 2004, 16 (3), 516-526.
48. Chaturvedi, R.K.; Shukla, S.; Seth, K.; Agrawal, A.K. Zuckerkandl's organ improves long-term survival and function of neural stem cell derived dopaminergic neurons in Parkinsonian rats. Exp. Neurol., 2008, 210 (2), 608-623.
49. Shukla, S.; Agrawal, A.K.; Chaturvedi, R.K.; Seth, K.; Srivastava, N.; Sinha, C.; Shukla, Y.; Khanna, V.K.; Seth, P.K. Cotransplantation of carotid body and ventral mesencephalic cells as an alternative approach towards functional restoration in 6-hydroxydopamine-lesioned rats: implications for Parkinson's disease. J. Neurochem., 2004, 91 (2), 274-284.
50. Shukla, S.; Chaturvedi, R.K.; Seth, K.; Roy, N.S.; Agrawal, A.K. Enhanced survival and function of neural stem cells-derived dopaminergic neurons under influence of olfactory ensheathing cells in parkinsonian rats. J. Neurochem., 2009, 109 (2), 436-451.
51. Schindowski, K.; Belarbi, K.; Buee, L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav., 2008, 7 Suppl 1, 43-56.
52. Schulte-Herbruggen, O.; Jockers-Scherubl, M.C.; Hellweg, R. Neurotrophins: from pathophysiology to treatment in Alzheimer's disease. Curr. Alzheimer Res., 2008, 5 (1), 38-44.
53. Calissano, P.; Matrone, C.; Amadoro, G. Nerve growth factor as a paradigm of neurotrophins related to Alzheimer's disease. Dev. Neurobiol., 2010, 70 (5), 372-383.
54. Eriksdotter Jonhagen, M.; Nordberg, A.; Amberla, K.; Backman, L.; Ebendal, T.; Meyerson, B.; Olson, L.; Seiger; Shigeta, M.; Theodorsson, E.; Viitanen, M.; Winblad, B.; Wahlund, L.O. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 1998, 9 (5), 246-257.
55. Day-Lollini, P.A.; Stewart, G.R.; Taylor, M.J.; Johnson, R.M.; Chellman, G.J. Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Exp. Neurol., 1997, 145 (1), 24-37.
56. Tuszynski, M.H.; Thal, L.; Pay, M.; Salmon, D.P.; U, H.S.; Bakay, R.; Patel, P.; Blesch, A.; Vahlsing, H.L.; Ho, G.; Tong, G.; Potkin, S.G.; Fallon, J.; Hansen, L.; Mufson, E.J.; Kordower, J.H.; Gall, C.; Conner, J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med., 2005, 11 (5), 551-555.
57. Mandel, R.J. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr. Opin. Mol. Ther., 2010, 12 (2), 240-247.
58. Marks, W.J., Jr.; Ostrem, J.L.; Verhagen, L.; Starr, P.A.; Larson, P.S.; Bakay, R.A.; Taylor, R.; Cahn-Weiner, D.A.; Stoessl, A.J.; Olanow, C.W.; Bartus, R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an openlabel, phase I trial. Lancet Neurol., 2008, 7 (5), 400-408.
59. Nutt, J.G.; Burchiel, K.J.; Comella, C.L.; Jankovic, J.; Lang, A.E.; Laws, E.R., Jr.; Lozano, A.M.; Penn, R.D.; Simpson, R.K., Jr.; Stacy, M.; Wooten, G.F. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology, 2003, 60 (1), 69-73.
60. Gill, S.S.; Patel, N.K.; Hotton, G.R.; O'Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.J.; Svendsen, C.N.; Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 2003, 9 (5), 589-595.
61. Slevin, J.T.; Gash, D.M.; Smith, C.D.; Gerhardt, G.A.; Kryscio, R.; Chebrolu, H.; Walton, A.; Wagner, R.; Young, A.B. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg., 2007, 106 (4), 614-620.
62. Slevin, J.T.; Gerhardt, G.A.; Smith, C.D.; Gash, D.M.; Kryscio, R.; Young, B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg., 2005, 102 (2), 216-222.
63. Ochs, G.; Penn, R.D.; York, M.; Giess, R.; Beck, M.; Tonn, J.; Haigh, J.; Malta, E.; Traub, M.; Sendtner, M.; Toyka, K.V. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2000, 1 (3), 201-206.
64. Beal, M.F.; Martin, J.B. Neuropeptides in neurological disease. Ann. Neurol., 1986, 20 (5), 547-565.
65. Wahlestedt, C.; Ekman, R.; Widerlov, E. Neuropeptide Y (NPY) and the central nervous system: distribution effects and possible relationship to neurological and psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry., 1989, 13 (1-2), 31-54.
66. van den Pol, A.N. Neuropeptide transmission in brain circuits. Neuron, 2012, 76 (1), 98-115.
67. Serova, L.I.; Tillinger, A.; Alaluf, L.G.; Laukova, M.; Keegan, K.; Sabban, E.L. Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats. Neuroscience., 2013, 16, 298-312.
68. Ito, N.; Hori, A.; Yabe, T.; Nagai, T.; Oikawa, T.; Yamada, H.; Hanawa, T. Involvement of neuropeptide Y signaling in the antidepressant-like effect and hippocampal cell proliferation induced by kososan, a Kampo medicine, in the stress-induced depression-like model mice. Biol. Pharm. Bull., 2012, 35 (10), 1775-1783.
69. Croce, N.; Ciotti, M.T.; Gelfo, F.; Cortelli, S.; Federici, G.; Caltagirone, C.; Bernardini, S.; Angelucci, F. Neuropeptide Y protects rat cortical neurons against beta-amyloid toxicity and reestablishes synthesis and release of nerve growth factor. ACS Chem. Neurosci., 2012, 3 (4), 312-318.
70. Goto, S.; Kawarai, T.; Morigaki, R.; Okita, S.; Koizumi, H.; Nagahiro, S.; Munoz, E.L.; Lee, L.V.; Kaji, R. Defects in the striatal neuropeptide Y system in X-linked dystonia-parkinsonism. Brain, 2013, 136 (Pt 5), 1555-1567.
71. Heilig, M.; Sjogren, M.; Blennow, K.; Ekman, R.; Wallin, A. Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia. Biol. Psychiatry, 1995, 38 (4), 210-216.
72. Koide, S.; Onishi, H.; Hashimoto, H.; Kai, T.; Yamagami, S. Plasma neuropeptide Y is reduced in patients with Alzheimer's disease. Neurosci. Lett., 1995, 198 (2), 149-151.
73. Qureshi, G.A.; Baig, S.M.; Parvez, S.H. Variation in cerebrospinal fluid levels of neuropeptide Y, cholecystokinin and substance P in patients with neurological disorders. Neuro. Endocrinol. Lett., 2000, 21 (5), 409-416.
74. Beal, M.F.; Clevens, R.A.; Mazurek, M.F. Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes. Synapse, 1988, 2 (4), 463-467.
75. Minthon, L.; Edvinsson, L.; Gustafson, L. Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. Dement. Geriatr. Cogn. Disord., 1997, 8 (4), 232-239.
76. Jimenez-Corral, C.; Moran-Sanchez, J.C.; Alonso-Navarro, H. [Neuropeptides in Alzheimer's disease]. Rev Neurol., 2006, 42 (6), 354-359.
77. Decressac, M.; Pain, S.; Chabeauti, P.Y.; Frangeul, L.; Thiriet, N.; Herzog, H.; Vergote, J.; Chalon, S.; Jaber, M.; Gaillard, A. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol. Aging, 2012, 33 (9), 2125-2137.
78. Rose, J.B.; Crews, L.; Rockenstein, E.; Adame, A.; Mante, M.; Hersh, L.B.; Gage, F.H.; Spencer, B.; Potkar, R.; Marr, R.A.; Masliah, E. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. J. Neurosci., 2009, 29 (4), 1115-1125.
79. Croce, N.; Gelfo, F.; Ciotti, M.T.; Federici, G.; Caltagirone, C.; Bernardini, S.; Angelucci, F. NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model of Alzheimer disease: a possible role in neuroprotection? Mol. Cell Biochem., 2013, 376 (1-2), 189-195.
80. Malva, J.O.; Xapelli, S.; Baptista, S.; Valero, J.; Agasse, F.; Ferreira, R.; Silva, A.P. Multifaces of neuropeptide Y in the brain-neuroprotection, neurogenesis and neuroinflammation. Neuropeptides, 2012, 46 (6), 299-308.
81. Corvino, V.; Marchese, E.; Giannetti, S.; Lattanzi, W.; Bonvissuto, D.; Biamonte, F.; Mongiovi, A.M.; Michetti, F.; Geloso, M.C. The neuroprotective and neurogenic effects of neuropeptide Y administration in an animal model of hippocampal neurodegeneration and temporal lobe epilepsy induced by trimethyltin. J. Neurochem., 2012, 122(2), 415-426.
82. Cheung, A.; Newland, P.L.; Zaben, M.; Attard, G.S.; Gray, W.P. Intracellular nitric oxide mediates neuroproliferative effect of neuropeptide y on postnatal hippocampal precursor cells. J. Biol. Chem., 2012, 287 (24), 20187-20196.
83. Drexel, M.; Kirchmair, E.; Wieselthaler-Holzl, A.; Preidt, A.P.; Sperk, G. Somatostatin and neuropeptide Y neurons undergo different plasticity in parahippocampal regions in kainic acid-induced epilepsy. J. Neuropathol. Exp. Neurol., 2012, 71 (4), 312-329.
84. Smialowska, M.; Domin, H.; Zieba, B.; Kozniewska, E.; Michalik, R.; Piotrowski, P.; Kajta, M. Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides, 2009, 43 (3), 235-249.
85. Xapelli, S.; Bernardino, L.; Ferreira, R.; Grade, S.; Silva, A.P.; Salgado, J.R.; Cavadas, C.; Grouzmann, E.; Poulsen, F.R.; Jakobsen, B.; Oliveira, C.R.; Zimmer, J.; Malva, J.O. Interaction between neuropeptide Y (NPY) and brain-derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia. Eur. J. Neurosc., 2008, 27 (8), 2089-2102.
86. Horne, E.A.; Coy, J.; Swinney, K.; Fung, S.; Cherry, A.E.; Marrs, W.R.; Naydenov, A.V.; Lin, Y.H.; Sun, X.; Dirk Keene, C.; Grouzmann, E.; Muchowski, P.; Bates, G.P.; Mackie, K.; Stella, N. Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. Eur. J. Neurosc., 2013, 37 (3), 429-440.
87. dos Santos, V.V.; Santos, D.B.; Lach, G.; Rodrigues, A.L.; Farina, M.; De Lima, T.C.; Prediger, R.D. Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid-beta (Abeta(1-40)) administration in mice. Behav. Brain Res., 2013, 244, 107-115.
88. Croce, N.; Dinallo, V.; Ricci, V.; Federici, G.; Caltagirone, C.; Bernardini, S.; Angelucci, F. Neuroprotective effect of neuropeptide Y against beta-amyloid 25-35 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production. Neurodegener. Dis., 2011, 8 (5), 300-309.
89. Decressac, M.; Wright, B.; Tyers, P.; Gaillard, A.; Barker, R.A. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp. Neurol., 2010, 226 (1), 24-32.
90. Plosker, G.L.; Gauthier, S. Cerebrolysin: a review of its use in dementia. Drugs Aging, 2009, 26 (11), 893-915.
91. Ubhi, K.; Rockenstein, E.; Vazquez-Roque, R.; Mante, M.; Inglis, C.; Patrick, C.; Adame, A.; Fahnestock, M.; Doppler, E.; Novak, P.; Moessler, H.; Masliah, E. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease. J. Neurosci. Res., 2013, 91 (2), 167-177.
92. Rockenstein, E.; Ubhi, K.; Doppler, E.; Novak, P.; Moessler, H.; Li, B.; Blanchard, J.; Grundke-Iqbal, I.; Iqbal, K.; Mante, M.; Adame, A.; Crews, L.; Masliah, E. Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AbetaPP transgenic mice. J. Alzheimers Dis., 2011, 27 (4), 743-752.
93. Anton Alvarez, X.; Fuentes, P. Cerebrolysin in Alzheimer's disease. Drugs Today (Barc.), 2011, 47 (7), 487-513.
94. Plosker, G.L.; Gauthier, S. Spotlight on cerebrolysin in dementia. CNS Drugs, 2010, 24 (3), 263-266.
95. Rockenstein, E.; Torrance, M.; Mante, M.; Adame, A.; Paulino, A.; Rose, J.B.; Crews, L.; Moessler, H.; Masliah, E. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J. Neurosci. Res., 2006, 83 (7), 1252-1261.
96. Gavrilova, S.I.; Fedorova Ia, B.; Kolykhalov, I.V.; Odinak, M.M.; Emelin, A.; Kashin, A.V.; Selezneva, N.D.; Kalyn Ia, B.; Roshchina, I.F. [The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease]. Zh Nevrol Psikhiatr Im S S Korsakova., 2008, 108 (8), 24-28.
97. Allegri, R.F.; Guekht, A. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia. Drugs Today (Barc), 2012, 48 Suppl A, 25-41.
98. Rockenstein, E.; Mante, M.; Adame, A.; Crews, L.; Moessler, H.; Masliah, E. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease. Acta neuropathologica, 2007, 113 (3), 265-275.
99. Tatebayashi, Y. [The dentate gyrus neurogenesis: a common therapeutic target for Alzheimer disease and senile depression?]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2003, 105 (4), 398-404.
100. Rockenstein, E.; Adame, A.; Mante, M.; Moessler, H.; Windisch, M.; Masliah, E. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J. Neural. Transm., 2003, 110 (11), 1313-1327.
101. Alvarez, X.A.; Sampedro, C.; Cacabelos, R.; Linares, C.; Aleixandre, M.; Garcia-Fantini, M.; Moessler, H. Reduced TNF-alpha and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin. Int. J. Neuropsychopharmacol., 2009, 12 (7), 867-872.
102. Rockenstein, E.; Adame, A.; Mante, M.; Larrea, G.; Crews, L.; Windisch, M.; Moessler, H.; Masliah, E. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J. Neural. Transm., 2005, 112 (2), 269-282.
103. Rockenstein, E.; Mallory, M.; Mante, M.; Alford, M.; Windisch, M.; Moessler, H.; Masliah, E. Effects of Cerebrolysin on amyloidbeta deposition in a transgenic model of Alzheimer's disease. J. Neural Transm., 2002, 62, 327-336.
104. Alvarez, X.A.; Lombardi, V.R.; Fernandez-Novoa, L.; Garcia, M.; Sampedro, C.; Cagiao, A.; Cacabelos, R.; Windisch, M. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J. Neural Transm. Suppl., 2000, 59, 281-292.
105. Menon, P.K.; Muresanu, D.F.; Sharma, A.; Mossler, H.; Sharma, H.S. Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS Neurol. Disord. Drug Targets, 2012, 11 (1), 40-49.
106. Alvarez, X.A.; Cacabelos, R.; Sampedro, C.; Couceiro, V.; Aleixandre, M.; Vargas, M.; Linares, C.; Granizo, E.; Garcia-Fantini, M.; Baurecht, W.; Doppler, E.; Moessler, H. In Curr. Alzheimer Res., 2011; Vol. 8, pp 583-591.
107. Juarez, I.; Gonzalez, D.J.; Mena, R.; Flores, G. The chronic administration of cerebrolysin induces plastic changes in the prefrontal cortex and dentate gyrus in aged mice. Synapse, 2011, 65 (11), 1128-1135.
108. Molloy, D.W.; Standish, T.I. Clinical experience with Cerebrolysin. J. Neural Transm., 2000, 59, 293-300.
109. Bae, C.Y.; Cho, C.Y.; Cho, K.; Hoon Oh, B.; Choi, K.G.; Lee, H.S.; Jung, S.P.; Kim, D.H.; Lee, S.; Choi, G.D.; Cho, H.; Lee, H. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease. J. Am. Geriatr. Soc., 2000, 48 (12), 1566-1571.
110. Alvarez, X.A.; Cacabelos, R.; Laredo, M.; Couceiro, V.; Sampedro, C.; Varela, M.; Corzo, L.; Fernandez-Novoa, L.; Vargas, M.; Aleixandre, M.; Linares, C.; Granizo, E.; Muresanu, D.; Moessler, H. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur. J. Neurol., 2006, 13 (1), 43-54.
111. Alvarez, X.A.; Cacabelos, R.; Sampedro, C.; Aleixandre, M.; Linares, C.; Granizo, E.; Doppler, E.; Moessler, H. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur. J. Neurol., 2011, 18 (1), 59-68.
112. Kotzbauer, P.T.; Lampe, P.A.; Heuckeroth, R.O.; Golden, J.P.; Creedon, D.J.; Johnson, E.M., Jr.; Milbrandt, J. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature, 1996, 384 (6608), 467-470.
113. Hurelbrink, C.B.; Barker, R.A. The potential of GDNF as a treatment for Parkinson's disease. Exp. Neurol., 2004, 185 (1), 1-6.
114. Horger, B.A.; Nishimura, M.C.; Armanini, M.P.; Wang, L.C.; Poulsen, K.T.; Rosenblad, C.; Kirik, D.; Moffat, B.; Simmons, L.; Johnson, E., Jr.; Milbrandt, J.; Rosenthal, A.; Bjorklund, A.; Vandlen, R.A.; Hynes, M.A.; Phillips, H.S. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci., 1998, 18 (13), 4929-4937.
115. Tseng, J.L.; Bruhn, S.L.; Zurn, A.D.; Aebischer, P. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy. Neuroreport, 1998, 9 (8), 1817-1822.
116. Rosenblad, C.; Kirik, D.; Devaux, B.; Moffat, B.; Phillips, H.S.; Bjorklund, A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkin son's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci., 1999, 11 (5), 1554-1566.
117. Oiwa, Y.; Yoshimura, R.; Nakai, K.; Itakura, T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res., 2002, 947 (2), 271-283.
118. Gasmi, M.; Herzog, C.D.; Brandon, E.P.; Cunningham, J.J.; Ramirez, G.A.; Ketchum, E.T.; Bartus, R.T. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol. Ther., 2007, 15 (1), 62-68.
119. Biju, K.C.; Santacruz, R.A.; Chen, C.; Zhou, Q.; Yao, J.; Rohrabaugh, S.L.; Clark, R.A.; Roberts, J.L.; Phillips, K.A.; Imam, S.Z.; Li, S. Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease. Neurosci. Lett., 2013, 535, 24-29.
120. Love, S.; Plaha, P.; Patel, N.K.; Hotton, G.R.; Brooks, D.J.; Gill, S.S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med., 2005, 11 (7), 703-704.
121. Patel, N.K.; Bunnage, M.; Plaha, P.; Svendsen, C.N.; Heywood, P.; Gill, S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol., 2005, 57 (2), 298-302.
122. McBride, J.L.; Kordower, J.H. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog. Brain Res,. 2002, 138, 421-432.
123. During, M.J.; Kaplitt, M.G.; Stern, M.B.; Eidelberg, D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum. Gene Ther., 2001, 12 (12), 1589-1591.
124. Treanor, J.J.; Goodman, L.; de Sauvage, F.; Stone, D.M.; Poulsen, K.T.; Beck, C.D.; Gray, C.; Armanini, M.P.; Pollock, R.A.; Hefti, F.; Phillips, H.S.; Goddard, A.; Moore, M.W.; Buj-Bello, A.; Davies, A.M.; Asai, N.; Takahashi, M.; Vandlen, R.; Henderson, C.E.; Rosenthal, A. Characterization of a multicomponent receptor for GDNF. Nature., 1996, 382 (6586), 80-83.
125. Klein, R.D.; Sherman, D.; Ho, W.H.; Stone, D.; Bennett, G.L.; Moffat, B.; Vandlen, R.; Simmons, L.; Gu, Q.; Hongo, J.A.; Devaux, B.; Poulsen, K.; Armanini, M.; Nozaki, C.; Asai, N.; Goddard, A.; Phillips, H.; Henderson, C.E.; Takahashi, M.; Rosenthal, A. A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature., 1997, 387 (6634), 717-721.
126. Baloh, R.H.; Tansey, M.G.; Golden, J.P.; Creedon, D.J.; Heuckeroth, R.O.; Keck, C.L.; Zimonjic, D.B.; Popescu, N.C.; Johnson, E.M., Jr.; Milbrandt, J. TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. Neuron., 1997, 18 (5), 793-802.
127. Creedon, D.J.; Tansey, M.G.; Baloh, R.H.; Osborne, P.A.; Lampe, P.A.; Fahrner, T.J.; Heuckeroth, R.O.; Milbrandt, J.; Johnson, E.M., Jr. Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proc. Natl. Acad. Sci. U S A, 1997, 94 (13), 7018-7023.
128. Widenfalk, J.; Nosrat, C.; Tomac, A.; Westphal, H.; Hoffer, B.; Olson, L. Neurturin and glial cell line-derived neurotrophic factor receptor-beta (GDNFR-beta), novel proteins related to GDNF and GDNFR-alpha with specific cellular patterns of expression suggesting roles in the developing and adult nervous system and in peripheral organs. J. Neurosci., 1997, 17 (21), 8506-8519.
129. Golden, J.P.; Baloh, R.H.; Kotzbauer, P.T.; Lampe, P.A.; Osborne, P.A.; Milbrandt, J.; Johnson, E.M., Jr. Expression of neurturin, GDNF, and their receptors in the adult mouse CNS. J. Comp .Neurol,. 1998, 398 (1), 139-150.
130. Burazin, T.C.; Gundlach, A.L. Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum. Brain Res. Mol. Brain Res., 1999, 73 (1-2), 151-171.
131. Fjord-Larsen, L.; Johansen, J.L.; Kusk, P.; Tornoe, J.; Gronborg, M.; Rosenblad, C.; Wahlberg, L.U. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp. Neurol., 2005, 195 (1), 49-60.
132. Ramaswamy, S.; McBride, J.L.; Han, I.; Berry-Kravis, E.M.; Zhou, L.; Herzog, C.D.; Gasmi, M.; Bartus, R.T.; Kordower, J.H. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol. Dis., 2009, 34 (1), 40-50.
133. Herzog, C.D.; Brown, L.; Gammon, D.; Kruegel, B.; Lin, R.; Wilson, A.; Bolton, A.; Printz, M.; Gasmi, M.; Bishop, K.M.; Kordower, J.H.; Bartus, R.T. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery, 2009, 64 (4), 602-612; discussion 612-603.
134. Bartus, R.T.; Herzog, C.D.; Chu, Y.; Wilson, A.; Brown, L.; Siffert, J.; Johnson, E.M., Jr.; Olanow, C.W.; Mufson, E.J.; Kordower, J.H. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord., 2011, 26 (1), 27-36.
135. Bartus, R.T.; Baumann, T.L.; Siffert, J.; Herzog, C.D.; Alterman, R.; Boulis, N.; Turner, D.A.; Stacy, M.; Lang, A.E.; Lozano, A.M.; Olanow, C.W. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology, 2013, 80 (18), 1698-1701.
136. Hickey, P.; Stacy, M. AAV2-neurturin (CERE-120) for Parkinson's disease. Expert Opin. Biol. Ther., 2013, 13 (1), 137-145.
137. Arborelius, L.; Owens, M.J.; Plotsky, P.M.; Nemeroff, C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol., 1999, 160 (1), 1-12.
138. Owens, M.J.; Nemeroff, C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev., 1991, 43 (4), 425-473.
139. Heuser, I.J.; Chase, T.N.; Mouradian, M.M. The limbichypothalamic- pituitary-adrenal axis in Huntington's disease. Biol. Psychiatry., 1991, 30 (9), 943-952.
140. Mizuno, Y.; Takahashi, K.; Totsune, K.; Ohneda, M.; Konno, H.; Murakami, O.; Satoh, F.; Sone, M.; Takase, S.; Itoyama, Y.; et al. Decrease in cerebellin and corticotropin-releasing hormone in the cerebellum of olivopontocerebellar atrophy and Shy-Drager syndrome. Brain Res., 1995, 686 (1), 115-118.
141. Suemaru, S.; Suemaru, K.; Kawai, K.; Miyata, S.; Nobukuni, K.; Ihara, Y.; Namba, R.; Urakami, K.; Hashimoto, K. Cerebrospinal fluid corticotropin- releasing hormone in neurodegenerative diseases: reduction in spinocerebellar degeneration. Life sciences., 1995, 57 (24), 2231-2235.
142. Dallman, M.F.; Akana, S.F.; Levin, N.; Walker, C.D.; Bradbury, M.J.; Suemaru, S.; Scribner, K.S. Corticosteroids and the control of function in the hypothalamo-pituitary-adrenal (HPA) axis. Ann. N. Y. Acad. Sci., 1994, 746, 22-31; discussion 31-22, 64-27.
143. De Souza, E.B. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology., 1995, 20 (8), 789-819.
144. Facci, L.; Stevens, D.A.; Pangallo, M.; Franceschini, D.; Skaper, S.D.; Strijbos, P.J. Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. Neuropharmacology., 2003, 45 (5), 623-636.
145. Perrin, M.H.; Vale, W.W. Corticotropin releasing factor receptors and their ligand family. Ann. N. Y. Acad. Sci., 1999, 885, 312-328.
146. Battaglia, G.; Webster, E.L.; De Souza, E.B. Characterization of corticotropin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system. Synapse., 1987, 1 (6), 572-581.
147. Van Pett, K.; Viau, V.; Bittencourt, J.C.; Chan, R.K.; Li, H.Y.; Arias, C.; Prins, G.S.; Perrin, M.; Vale, W.; Sawchenko, P.E. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol., 2000, 428 (2), 191-212.
148. Chalmers, D.T.; Lovenberg, T.W.; De Souza, E.B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci., 1995, 15 (10), 6340-6350.
149. Sanchez, M.M.; Young, L.J.; Plotsky, P.M.; Insel, T.R. Autoradiographic and in situ hybridization localization of corticotropinreleasing factor 1 and 2 receptors in nonhuman primate brain. J. Comp. Neurol., 1999, 408 (3), 365-377.
150. Dautzenberg, F.M.; Hauger, R.L. The CRF peptide family and their receptors: yet more partners discovered. Trends in Pharmacol. Sci., 2002, 23 (2), 71-77.
151. Behan, D.P.; Heinrichs, S.C.; Troncoso, J.C.; Liu, X.J.; Kawas, C.H.; Ling, N.; De Souza, E.B. Displacement of corticotropin re leasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature., 1995, 378 (6554), 284-287.
152. Behan, D.P.; Maciejewski, D.; Chalmers, D.; De Souza, E.B. Corticotropin releasing factor binding protein (CRF-BP) is expressed in neuronal and astrocytic cells. Brain Res., 1995, 698 (1-2), 259-264.
153. Whitehouse, P.J.; Vale, W.W.; Zweig, R.M.; Singer, H.S.; Mayeux, R.; Kuhar, M.J.; Price, D.L.; De Souza, E.B. Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy. Neurology., 1987, 37 (6), 905-909.
154. Dong, H.; Murphy, K.M.; Meng, L.; Montalvo-Ortiz, J.; Zeng, Z.; Kolber, B.J.; Zhang, S.; Muglia, L.J.; Csernansky, J.G. Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease. J. Alzheimers Dis., 2012, 28 (3), 579-592.
155. Lowery, E.G.; Thiele, T.E. Pre-clinical evidence that corticotropinreleasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism. CNS Neurol. Disord. Drug Targets., 2010, 9 (1), 77-86.
156. Pedersen, W.A.; McCullers, D.; Culmsee, C.; Haughey, N.J.; Herman, J.P.; Mattson, M.P. Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. Neurobiol. Dis., 2001, 8 (3), 492-503.
157. Rydel, R.E.; Greene, L.A. cAMP analogs promote survival and neurite outgrowth in cultures of rat sympathetic and sensory neurons independently of nerve growth factor. Proc. Natl. Acad. Sci. U S A., 1988, 85 (4), 1257-1261.
158. Mena, M.A.; Casarejos, M.J.; Bonin, A.; Ramos, J.A.; Garcia Yebenes, J. Effects of dibutyryl cyclic AMP and retinoic acid on the differentiation of dopamine neurons: prevention of cell death by dibutyryl cyclic AMP. J. Neurochem., 1995, 65 (6), 2612-2620.
159. D'Mello, S.R.; Galli, C.; Ciotti, T.; Calissano, P. Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc. Natl. Acad. Sci. U S A., 1993, 90 (23), 10989-10993.
160. Pedersen, W.A.; Wan, R.; Zhang, P.; Mattson, M.P. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J. Neurosci., 2002, 22 (2), 404-412.
161. Lezoualc'h, F.; Engert, S.; Berning, B.; Behl, C. Corticotropinreleasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappaB. J. Mol. Endocrinol. (Baltimore, Md, 2000, 14 (1), 147-159.
162. Fox, M.W.; Anderson, R.E.; Meyer, F.B. Neuroprotection by corticotropin releasing factor during hypoxia in rat brain. Stroke, 1993, 24 (7), 1072-1075; discussion 1075-1076.
163. Abuirmeileh, A.; Harkavyi, A.; Kingsbury, A.; Lever, R.; Whitton, P.S. The CRF-like peptide urocortin greatly attenuates loss of extracellular striatal dopamine in rat models of Parkinson's disease by activating CRF(1) receptors. Eur. J. Pharmacol., 2009, 604 (1-3), 45-50.
164. Abuirmeileh, A.; Lever, R.; Kingsbury, A.E.; Lees, A.J.; Locke, I.C.; Knight, R.A.; Chowdrey, H.S.; Biggs, C.S.; Whitton, P.S. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease. Eur. J. Neurosci., 2007, 26 (2), 417-423.
165. Kim, Y.; Park, M.K.; Chung, S. Protective effect of urocortin on 1-methyl-4-phenylpyridinium-induced dopaminergic neuronal death. Molecules and cells, 2010, 30 (5), 427-433.
166. Ying, G.; Iribarren, P.; Zhou, Y.; Gong, W.; Zhang, N.; Yu, Z.X.; Le, Y.; Cui, Y.; Wang, J.M. Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptorlike-1 as a functional receptor. J. Immunol., 2004, 172 (11), 7078-7085.
167. Sponne, I.; Fifre, A.; Koziel, V.; Kriem, B.; Oster, T.; Pillot, T. Humanin rescues cortical neurons from prion-peptide-induced apoptosis. Mol. Cell Neurosci., 2004, 25 (1), 95-102.
168. Zapala, B.; Kaczynski, L.; Kiec-Wilk, B.; Staszel, T.; Knapp, A.; Thoresen, G.H.; Wybranska, I.; Dembinska-Kiec, A. Humanins, the neuroprotective and cytoprotective peptides with antiapoptotic and anti-inflammatory properties. Pharmacol. Rep., 2010, 62 (5), 767-777.
169. Matsuoka, M. Humanin signal for Alzheimer's disease. J. Alzheimers Dis., 2011, 24 Suppl 2, 27-32.
170. Zhang, W.; Zhang, W.; Li, Z.; Hao, J.; Zhang, Z.; Liu, L.; Mao, N.; Miao, J.; Zhang, L. S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice. Pharmacol. Biochem. Behav., 2012, 100 (3), 361-369.
171. Niikura, T.; Sidahmed, E.; Hirata-Fukae, C.; Aisen, P.S.; Matsuoka, Y. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PloS one., 2011, 6 (1), e16259.
172. Matsuoka, M.; Hashimoto, Y. Humanin and the receptors for humanin. Mol. Neurobiol., 2010, 41 (1), 22-28.
173. Matsuoka, M. Humanin; a defender against Alzheimer's disease? Recent Pat. CNS Drug Discov., 2009, 4 (1), 37-42.
174. Chiba, T.; Yamada, M.; Sasabe, J.; Terashita, K.; Shimoda, M.; Matsuoka, M.; Aiso, S. Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons. Mol. psychiatry, 2009, 14 (2), 206-222.
175. Yamada, M.; Chiba, T.; Sasabe, J.; Terashita, K.; Aiso, S.; Matsuoka, M. Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease. Neuropsychopharmacology., 2008, 33 (8), 2020-2032.
176. Hashimoto, Y.; Suzuki, H.; Aiso, S.; Niikura, T.; Nishimoto, I.; Matsuoka, M. Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection. Life sciences, 2005, 77 (24), 3092-3104.
177. Matsuoka, M.; Hashimoto, Y.; Aiso, S.; Nishimoto, I. Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis. CNS Drug Rev., 2006, 12 (2), 113-122.
178. Chiba, T.; Yamada, M.; Hashimoto, Y.; Sato, M.; Sasabe, J.; Kita, Y.; Terashita, K.; Aiso, S.; Nishimoto, I.; Matsuoka, M. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J. Neurosci., 2005, 25 (44), 10252-10261.
179. Yuan, L.; Han, W.N.; Li, S.F.; Liu, X.J.; Wu, M.N.; Qi, J.S. [[Gly14]-humanin protects against Abeta(31-35)-induced impairment of spatial learning and memory in rats]. Sheng Li Xue Bao., 2012, 64 (6), 625-632.
180. Wang, T.; Zhang, L.; Zhang, M.; Bao, H.; Liu, W.; Wang, Y.; Wang, L.; Dai, D.; Chang, P.; Dong, W.; Chen, X.; Tao, L. [Gly14]-Humanin reduces histopathology and improves functional outcome after traumatic brain injury in mice. Neuroscience., 2013, 231, 70-81.
181. Kariya, S.; Takahashi, N.; Ooba, N.; Kawahara, M.; Nakayama, H.; Ueno, S. Humanin inhibits cell death of serum-deprived PC12h cells. Neuroreport., 2002, 13 (6), 903-907.
182. Zhao, S.T.; Huang, X.T.; Zhang, C.; Ke, Y. Humanin protects cortical neurons from ischemia and reperfusion injury by the increased activity of superoxide dismutase. Neurochem. Res., 2012, 37 (1), 153-160.
183. Hashimoto, Y.; Niikura, T.; Tajima, H.; Yasukawa, T.; Sudo, H.; Ito, Y.; Kita, Y.; Kawasumi, M.; Kouyama, K.; Doyu, M.; Sobue, G.; Koide, T.; Tsuji, S.; Lang, J.; Kurokawa, K.; Nishimoto, I. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc. Natl. Acad. Sci. USA., 2001, 98 (11), 6336-6341.
184. Nishimoto, I.; Matsuoka, M.; niikura, T. Unravelling the role of Humanin. Trends Mol. Med., 2004, 10 (3), 102-105.
185. Krejcova, G.; Patocka, J.; Slaninova, J. Effect of humanin analogues on experimentally induced impairment of spatial memory in rats. J. Pept. Sci., 2004, 10 (10), 636-639.
186. Kunesova, G.; Hlavacek, J.; Patocka, J.; Evangelou, A.; Zikos, C.; Benaki, D.; Paravatou-Petsotas, M.; Pelecanou, M.; Livaniou, E.; Slaninova, J. The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues. Peptides., 2008, 29 (11), 1982-1987.
187. Mamiya, T.; Ukai, M. [Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br. J. Pharmacol., 2001, 134 (8), 1597-1599.
188. Tajima, H.; Kawasumi, M.; Chiba, T.; Yamada, M.; Yamashita, K.; Nawa, M.; Kita, Y.; Kouyama, K.; Aiso, S.; Matsuoka, M.; Niikura, T.; Nishimoto, I. A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice. J. Neurosci. Res., 2005, 79 (5), 714-723.
189. Miao, J.; Zhang, W.; Yin, R.; Liu, R.; Su, C.; Lei, G.; Li, Z. S14GHumanin ameliorates Abeta25-35-induced behavioral deficits by reducing neuroinflammatory responses and apoptosis in mice. Neuropeptides., 2008, 42 (5-6), 557-567.
190. Dejda, A.; Sokolowska, P.; Nowak, J.Z. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol. Rep., 2005, 57 (3), 307-320.
191. Morell, M.; Souza-Moreira, L.; Gonzalez-Rey, E. VIP in neurological diseases: more than a neuropeptide. Endocr. Metab. Immune Disord. Drug Targets, 2012, 12 (4), 323-332.
192. Gonzalez-Rey, E.; Varela, N.; Chorny, A.; Delgado, M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr. Pharm. Des., 2007, 13 (11), 1113-1139.
193. Gonzalez-Rey, E.; Chorny, A.; Fernandez-Martin, A.; Varela, N.; Delgado, M. Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. Expert Opin. Ther. Targets, 2005, 9 (5), 923-929.
194. Delgado, M.; Ganea, D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. Faseb J., 2003, 17 (13), 1922-1924.
195. Delgado, M.; Ganea, D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. Faseb J., 2003, 17 (8), 944-946.
196. White, C.M.; Ji, S.; Cai, H.; Maudsley, S.; Martin, B. Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. CNS Neurol. Disord. Drug Targets, 2010, 9 (5), 661-666.
197. Gressens, P. VIP neuroprotection against excitotoxic lesions of the developing mouse brain. Ann. N.Y. Acad. Sci., 1999, 897, 109-124.
198. Leker, R.R.; Teichner, A.; Grigoriadis, N.; Ovadia, H.; Brenneman, D.E.; Fridkin, M.; Giladi, E.; Romano, J.; Gozes, I. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke; J. Cereb. Circulat., 2002, 33 (4), 1085-1092.
199. Offen, D.; Sherki, Y.; Melamed, E.; Fridkin, M.; Brenneman, D.E.; Gozes, I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res., 2000, 854 (1-2), 257-262.
200. Onoue, S.; Endo, K.; Ohshima, K.; Yajima, T.; Kashimoto, K. The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides., 2002, 23 (8), 1471-1478.
201. Tuncel, N.; Sener, E.; Cerit, C.; Karasu, U.; Gurer, F.; Sahinturk, V.; Baycu, C.; Ak, D.; Filiz, Z. Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy. Peptides., 2005, 26 (5), 827-836.
202. Sari, Y. Activity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse. Neuroscience., 2009, 158 (4), 1426-1435.
203. Sari, Y.; Weedman, J.M.; Nkrumah-Abrokwah, M. Neurotrophic peptides, ADNF-9 and NAP, prevent alcohol-induced apoptosis at midgestation in fetal brains of C57BL/6 mouse. J. Mol. Neurosci., 2013, 49 (1), 150-156.
204. Sokolowska, P.; Dejda, A.; Nowak, J.Z. [Neuroprotective role of PACAP, VIP, and PHI in the central nervous system]. Postepy. Hig. Med. Dosw. (Online)., 2004, 58, 416-427.
205. Fernandez-Montesinos, R.; Torres, M.; Baglietto-Vargas, D.; Gutierrez, A.; Gozes, I.; Vitorica, J.; Pozo, D. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J. Mol. Neurosci., 2010, 41 (1), 114-120.
206. Gozes, I.; Brenneman, D.E. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J. Mol. Neurosci., 1996, 7 (4), 235-244.
207. Zhou, J.N.; Hofman, M.A.; Swaab, D.F. VIP neurons in the human SCN in relation to sex, age, and Alzheimer's disease. Neurobiol. Aging., 1995, 16 (4), 571-576.
208. Jolkkonen, J.; Hartikainen, P.; Soikkeli, R.; Bissette, G.; Nemeroff, C.; Riekkinen, P. A correlation study of CSF neuropeptides in Alzheimer's and Parkinson's disease. Neuropeptides., 1991, 19 (2), 97-102.
209. Korkmaz, O.; Ay, H.; Ulupinar, E.; Tuncel, N. Vasoactive intestinal peptide enhances striatal plasticity and prevents dopaminergic cell loss in Parkinsonian rats. J. Mol. Neurosci., 2012, 48 (3), 565-573.
210. Korkmaz, O.T.; Tuncel, N.; Tuncel, M.; Oncu, E.M.; Sahinturk, V.; Celik, M. Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells. J. Mol. Neurosci., 2010, 41 (2), 278-287.
211. Tuncel, N.; Korkmaz, O.T.; Tekin, N.; Sener, E.; Akyuz, F.; Inal, M. Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum. J. Mol. Neurosci., 2012, 46 (1), 51-57.
212. Deguil, J.; Jailloux, D.; Page, G.; Fauconneau, B.; Houeto, J.L.; Philippe, M.; Muller, J.M.; Pain, S. Neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in MPP+-induced alteration of translational control in Neuro-2a neuroblastoma cells. J. Neurosci. Res., 2007, 85 (9), 2017-2025.
213. Dogrukol-Ak, D.; Tore, F.; Tuncel, N. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr. Pharm. Des., 2004, 10 (12), 1325-1340.
214. Jouroukhin, Y.; Ostritsky, R.; Gozes, I. D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. J. Mol. Neurosci., 2012, 48 (3), 597-602.
215. Sokolowska, P.; Passemard, S.; Mok, A.; Schwendimann, L.; Gozes, I.; Gressens, P. Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy. Neuroscience., 2011, 173, 156-168.
216. Gozes, I. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides, 2011, 32 (2), 428-431.
217. Fitzgerald, D.M.; Charness, M.E.; Leite-Morris, K.A.; Chen, S. Effects of ethanol and NAP on cerebellar expression of the neural cell adhesion molecule L1. PLoS One., 2011, 6 (9), e24364.
218. Greggio, S.; de Paula, S.; de Oliveira, I.M.; Trindade, C.; Rosa, R.M.; Henriques, J.A.; DaCosta, J.C. NAP prevents acute cerebral oxidative stress and protects against long-term brain injury and cognitive impairment in a model of neonatal hypoxia-ischemia. Neurobiol. Dis., 2011, 44 (1), 152-159.
219. Oz, S.; Ivashko-Pachima, Y.; Gozes, I. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One., 2012, 7 (12), e51458.
220. Shiryaev, N.; Jouroukhin, Y.; Giladi, E.; Polyzoidou, E.; Grigoriadis, N.C.; Rosenmann, H.; Gozes, I. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol. Dis., 2009, 34 (2), 381-388.
221. Greggio, S.; Rosa, R.M.; Dolganov, A.; de Oliveira, I.M.; Menegat, F.D.; Henriques, J.A.; Dacosta, J.C. NAP prevents hippocampal oxidative damage in neonatal rats subjected to hypoxia-induced seizures. Neurobiol. Dis., 2009, 36 (3), 435-444.
222. Fleming, S.M.; Mulligan, C.K.; Richter, F.; Mortazavi, F.; Lemesre, V.; Frias, C.; Zhu, C.; Stewart, A.; Gozes, I.; Morimoto, B.; Chesselet, M.F. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol. Cell. Neurosci., 2011, 46 (3), 597-606.
223. Sharma, N.K.; Sethy, N.K.; Meena, R.N.; Ilavazhagan, G.; Das, M.; Bhargava, K. Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain. Peptides., 2011, 32 (6), 1217-1224.
224. Zemlyak, I.; Manley, N.; Vulih-Shultzman, I.; Cutler, A.B.; Graber, K.; Sapolsky, R.M.; Gozes, I. The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J. Neurochem., 2009, 111 (5), 1252-1263.
225. Jarmula, A.; Stepkowski, D. The beta-sheet breakers and pistacking. J. Pept. Sci., 2013, 19 (6), 345-349.
226. Popiel, H.A.; Burke, J.R.; Strittmatter, W.J.; Oishi, S.; Fujii, N.; Takeuchi, T.; Toda, T.; Wada, K.; Nagai, Y. The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases. J. Amino Acids., 2011, 2011, 265084.
227. Popiel, H.A.; Takeuchi, T.; Burke, J.R.; Strittmatter, W.J.; Toda, T.; Wada, K.; Nagai, Y. Inhibition of Protein Misfolding/ Aggregation Using Polyglutamine Binding Peptide QBP1 as a Therapy for the Polyglutamine Diseases. Neurotherapeutics., 2013, 10 (3), 440-446.
228. Nagai, Y.; Fujikake, N.; Ohno, K.; Higashiyama, H.; Popiel, H.A.; Rahadian, J.; Yamaguchi, M.; Strittmatter, W.J.; Burke, J.R.; Toda, T. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum. Mol. Genet., 2003, 12 (11), 1253-1259.
229. Bauer, P.O.; Goswami, A.; Wong, H.K.; Okuno, M.; Kurosawa, M.; Yamada, M.; Miyazaki, H.; Matsumoto, G.; Kino, Y.; Nagai, Y.; Nukina, N. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat. Biotechnol., 2010, 28 (3), 256-263.
230. Tomita, K.; Popiel, H.A.; Nagai, Y.; Toda, T.; Yoshimitsu, Y.; Ohno, H.; Oishi, S.; Fujii, N. Structure-activity relationship study on polyglutamine binding peptide QBP1. Bioorg. Med. Chem., 2009, 17 (3), 1259-1263.
231. Armen, R.S.; Bernard, B.M.; Day, R.; Alonso, D.O.; Daggett, V. Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases. Proc. Natl. Acad. Sci. U S A, 2005, 102 (38), 13433-13438.
232. Ogoshi, M.; Inoue, K.; Naruse, K.; Takei, Y. Evolutionary history of the calcitonin gene-related peptide family in vertebrates revealed by comparative genomic analyses. Peptides., 2006, 27 (12), 3154-3164.
233. McLatchie, L.M.; Fraser, N.J.; Main, M.J.; Wise, A.; Brown, J.; Thompson, N.; Solari, R.; Lee, M.G.; Foord, S.M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature., 1998, 393 (6683), 333-339.
234. Zimmermann, U.; Fischer, J.A.; Frei, K.; Fischer, A.H.; Reinscheid, R.K.; Muff, R. Identification of adrenomedullin receptors in cultured rat astrocytes and in neuroblastboma x glioma hybrid cells (NG108-15). Brain Res., 1996, 724 (2), 238-245.
235. Xu, Y.; Krukoff, T.L. Adrenomedullin stimulates nitric oxide production from primary rat hypothalamic neurons: roles of calcium and phosphatases. Mol. Pharmacol., 2007, 72 (1), 112-120.
236. Mocco, J.; Sughrue, M.E.; Ducruet, A.F.; Komotar, R.J.; Sosunov, S.A.; Connolly, E.S., Jr. The complement system: a potential target for stroke therapy. Adv. Exp. Med. Biol., 2006, 586, 189-201.
237. Szeplaki, G.; Varga, L.; Fust, G.; Prohaszka, Z. Role of complement in the pathomechanism of atherosclerotic vascular diseases. Mol. Immunol., 2009, 46 (14), 2784-2793.
238. Sewell, D.L.; Nacewicz, B.; Liu, F.; Macvilay, S.; Erdei, A.; Lambris, J.D.; Sandor, M.; Fabry, Z. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J. Neuroimmunol., 2004, 155 (1-2), 55-63.
239. Bellander, B.M.; Olafsson, I.H.; Ghatan, P.H.; Bro Skejo, H.P.; Hansson, L.O.; Wanecek, M.; Svensson, M.A. Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochir. (Wien), 2011, 153 (1), 90-100.
240. Kolev, M.V.; Ruseva, M.M.; Harris, C.L.; Morgan, B.P.; Donev, R.M. Implication of complement system and its regulators in Alzheimer's disease. Curr. Neuropharmacol., 2009, 7 (1), 1-8.
241. Arumugam, T.V.; Woodruff, T.M.; Lathia, J.D.; Selvaraj, P.K.; Mattson, M.P.; Taylor, S.M. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience., 2009, 158 (3), 1074-1089.
242. Kitamura, K.; Kangawa, K.; Kawamoto, M.; Ichiki, Y.; Nakamura, S.; Matsuo, H.; Eto, T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun., 2012, 425 (3), 548-555.
243. Kis, B.; Deli, M.A.; Kobayashi, H.; Abraham, C.S.; Yanagita, T.; Kaiya, H.; Isse, T.; Nishi, R.; Gotoh, S.; Kangawa, K.; Wada, A.; Greenwood, J.; Niwa, M.; Yamashita, H.; Ueta, Y. Adrenomedullin regulates blood-brain barrier functions in vitro. Neuroreport., 2001, 12 (18), 4139-4142.
244. Fernandez, A.P.; Serrano, J.; Tessarollo, L.; Cuttitta, F.; Martinez, A. Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions. Proc. Natl. Acad. Sci. U S A, 2008, 105 (34), 12581-12586.
245. Serrano, J.; Fernandez, A.P.; Sanchez, J.; Rodrigo, J.; Martinez, A. Adrenomedullin expression is up-regulated by acute hypobaric hypoxia in the cerebral cortex of the adult rat. Brain pathol. (Zurich, Switzerland), 2008, 18 (3), 434-442.
246. Takahashi, K.; Nakayama, M.; Totsune, K.; Murakami, O.; Sone, M.; Kitamuro, T.; Yoshinoya, A.; Shibahara, S. Increased secretion of adrenomedullin from cultured human astrocytes by cytokines. J. Neurochem., 2000, 74 (1), 99-103.
247. Veroni, C.; Gabriele, L.; Canini, I.; Castiello, L.; Coccia, E.; Remoli, M.E.; Columba-Cabezas, S.; Arico, E.; Aloisi, F.; Agresti, C. Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. Mol. Cell. Neurosci., 2010, 45 (3), 234-244.
248. Uezono, Y.; Nakamura, E.; Ueda, Y.; Shibuya, I.; Ueta, Y.; Yokoo, H.; Yanagita, T.; Toyohira, Y.; Kobayashi, H.; Yanagihara, N.; Wada, A. Production of cAMP by adrenomedullin in human oligodendroglial cell line KG1C: comparison with calcitonin generelated peptide and amylin. Brain Res. Mol .Brain. Res., 2001, 97 (1), 59-69.
249. Zudaire, E.; Martinez, A.; Ozbun, L.L.; Cuttitta, F. Characterization of adrenomedullin in non-human primates. Biochem. Biophys. Res. Commun., 2004, 321 (4), 859-869.
250. Xia, C.F.; Yin, H.; Borlongan, C.V.; Chao, J.; Chao, L. Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Exp.Neurol., 2006, 197 (2), 521-530.
251. Armstead, W.M.; Riley, J.; Kiessling, J.W.; Cines, D.B.; Higazi, A.A. PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia. Am. J. Physiol. Heart. Circ. Physiol., 2010, 299 (1), H76-80.
252. Armstead, W.M.; Kiessling, J.W.; Bdeir, K.; Kofke, W.A.; Vavilala, M.S. Adrenomedullin prevents sex-dependent impairment of autoregulation during hypotension after piglet brain injury through inhibition of ERK MAPK upregulation. J. Neurotrauma., 2010, 27 (2), 391-402.
253. Temmesfeld-Wollbruck, B.; Hocke, A.C.; Suttorp, N.; Hippenstiel, S. Adrenomedullin and endothelial barrier function. Thromb. Haemost., 2007, 98 (5), 944-951.
254. Vitiello, G.; Grimaldi, M.; D'Ursi, A.M.; D'Errico, G. The iAbeta5p beta-breaker peptide regulates the Abeta(25-35) interaction with lipid bilayers through a cholesterol-mediated mechanism. Biochem. Biophys. Res. Commun., 2012, 417 (1), 88-92.
255. Jensen, M.; Canning, A.; Chiha, S.; Bouquerel, P.; Pedersen, J.T.; Ostergaard, J.; Cuvillier, O.; Sasaki, I.; Hureau, C.; Faller, P. Inhibition of Cu-amyloid-beta by using bifunctional peptides with betasheet breaker and chelator moieties. Chemistry., 2012, 18 (16), 4836-4839.
256. De Bona, P.; Giuffrida, M.L.; Caraci, F.; Copani, A.; Pignataro, B.; Attanasio, F.; Cataldo, S.; Pappalardo, G.; Rizzarelli, E. Design and synthesis of new trehalose-conjugated pentapeptides as inhibitors of Abeta(1-42) fibrillogenesis and toxicity. J. Pept. Sci., 2009, 15 (3), 220-228.
257. Chacon, M.A.; Barria, M.I.; Soto, C.; Inestrosa, N.C. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry, 2004, 9 (10), 953-961.
258. Soto, C.; Sigurdsson, E.M.; Morelli, L.; Kumar, R.A.; Castano, E.M.; Frangione, B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med., 1998, 4 (7), 822-826.
259. Permanne, B.; Adessi, C.; Saborio, G.P.; Fraga, S.; Frossard, M.J.; Van Dorpe, J.; Dewachter, I.; Banks, W.A.; Van Leuven, F.; Soto, C. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. Faseb J., 2002, 16 (8), 860-862.
260. Soto, C.; Saborio, G.P.; Permanne, B. Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy. Acta. Neurol. Scand., 2000, 176, 90-95.
261. Poduslo, J.F.; Curran, G.L.; Kumar, A.; Frangione, B.; Soto, C. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J. Neurobiol., 1999, 39 (3), 371-382.
262. Zhang, L.; Yagnik, G.; Peng, Y.; Wang, J.; Xu, H.H.; Hao, Y.; Liu, Y.N.; Zhou, F. Kinetic studies of inhibition of the amyloid beta (1-42) aggregation using a ferrocene-tagged beta-sheet breaker peptide. Anal. Biochem., 2013, 434 (2), 292-299.
263. Zheng, Y.J.; Wang, X.R.; Chen, H.Z.; Wu, X.J.; Zhao, Y.H.; Su, D.S. Protective effects of the delta opioid peptide [D-Ala2, D Leu5]enkephalin in an ex vivo model of ischemia/reperfusion in brain slices. CNS Neurosci. Ther., 2012, 18 (9), 762-766.
264. Kim, H.; Lee, S.W.; Park, J.S.; Min, J.H.; Kim, H.K. Genomic analysis of [d-Ala2, d-Leu5] enkephalin preconditioning in cortical neuron and glial cell injury after oxygen deprivation. Brain Res., 2012, 1447, 91-105.
265. Ananth, S.; Thakkar, S.V.; Gnana-Prakasam, J.P.; Martin, P.M.; Ganapathy, P.S.; Smith, S.B.; Ganapathy, V. Transport of the synthetic opioid peptide DADLE ([D-Ala2,D-Leu5]-enkephalin) in neuronal cells. J. Pharm. Sci., 2012, 101 (1), 154-163.
266. Duan, Y.L.; Wang, S.Y.; Zeng, Q.W.; Su, D.S.; Li, W.; Wang, X.R.; Zhao, Z. Astroglial reaction to delta opioid peptide [D-Ala2, D-Leu5] enkephalin confers neuroprotection against global ischemia in the adult rat hippocampus. Neuroscience, 2011, 192, 81-90.
267. Wang, S.; Duan, Y.; Su, D.; Li, W.; Tan, J.; Yang, D.; Wang, W.; Zhao, Z.; Wang, X. Delta opioid peptide [D-Ala2, D-Leu5] enkephalin (DADLE) triggers postconditioning against transient forebrain ischemia. Eur. J. Pharmacol., 2011, 658 (2-3), 140-144.
268. Ke, S.; Dian-san, S.; Xiang-rui, W. Delta opioid agonist [D-Ala2, D-Leu5] enkephalin (DADLE) reduced oxygen-glucose deprivation caused neuronal injury through the MAPK pathway. Brain Res., 2009, 1292, 100-106.
269. Ouyang, H.; Andersen, T.E.; Chen, W.; Nofsinger, R.; Steffansen, B.; Borchardt, R.T. A comparison of the effects of p-glycoprotein inhibitors on the blood-brain barrier permeation of cyclic prodrugs of an opioid peptide (DADLE). J. Pharm. Sci., 2009, 98 (6), 2227-2236.
270. Rodriguez-Cuenca, S.; Cocheme, H.M.; Logan, A.; Abakumova, I.; Prime, T.A.; Rose, C.; Vidal-Puig, A.; Smith, A.C.; Rubinsztein, D.C.; Fearnley, I.M.; Jones, B.A.; Pope, S.; Heales, S.J.; Lam, B.Y.; Neogi, S.G.; McFarlane, I.; James, A.M.; Smith, R.A.; Murphy, M.P. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radical Biol. Med., 2010, 48 (1), 161-172.
271. Chaturvedi, R.K.; Beal, M.F. PPAR: a therapeutic target in Parkinson's disease. J. Neurochem., 2008, 106 (2), 506-518.
272. Chaturvedi, R.K.; Flint Beal, M. Mitochondrial diseases of the brain. Free Radical Biol. Med., 2013, 63, 1-29.
273. Chaturvedi, R.K.; Beal, M.F. Mitochondrial approaches for neuroprotection. Ann. N. Y. Acad. Sci., 2008, 1147, 395-412.
274. Reddy, P.H. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol., 2006, 2006 (3), 31372.
275. Reddy, P.H.; Beal, M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med., 2008, 14 (2), 45-53.
276. Murphy, M.P.; Smith, R.A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 629-656.
277. Szeto, H.H. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. The AAPS journal, 2006, 8 (3), E521-531.
278. Sheu, S.S.; Nauduri, D.; Anders, M.W. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochimica. Biophysica. Acta., 2006, 1762 (2), 256-265.
279. Reddy, P.H.; Tripathi, R.; Troung, Q.; Tirumala, K.; Reddy, T.P.; Anekonda, V.; Shirendeb, U.P.; Calkins, M.J.; Reddy, A.P.; Mao, P.; Manczak, M. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim. Biophys. Acta., 2012, 1822 (5), 639-649.
280. Schiller, P.W.; Nguyen, T.M.; Berezowska, I.; Dupuis, S.; Weltrowska, G.; Chung, N.N.; Lemieux, C. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem., 2000, 35 (10), 895-901.
281. Zhao, G.M.; Qian, X.; Schiller, P.W.; Szeto, H.H. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors. J. Pharm. Exp. Ther., 2003, 307 (3), 947-954.
282. Zhao, K.; Zhao, G.M.; Wu, D.; Soong, Y.; Birk, A.V.; Schiller, P.W.; Szeto, H.H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem., 2004, 279 (33), 34682-34690.
283. Cho, S.; Szeto, H.H.; Kim, E.; Kim, H.; Tolhurst, A.T.; Pinto, J.T. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J. Biol. Chem., 2007, 282 (7), 4634-4642.
284. Petri, S.; Kiaei, M.; Damiano, M.; Hiller, A.; Wille, E.; Manfredi, G.; Calingasan, N.Y.; Szeto, H.H.; Beal, M.F. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem., 2006, 98 (4), 1141-1148.
285. Thomas, D.A.; Stauffer, C.; Zhao, K.; Yang, H.; Sharma, V.K.; Szeto, H.H.; Suthanthiran, M. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. J. Am. Soc. Nephrol., 2007, 18 (1), 213-222.
286. James, A.M.; Sharpley, M.S.; Manas, A.R.; Frerman, F.E.; Hirst, J.; Smith, R.A.; Murphy, M.P. Interaction of the mitochondriatargeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J. Biol. Chem., 2007, 282 (20), 14708-14718.
287. Kelso, G.F.; Porteous, C.M.; Coulter, C.V.; Hughes, G.; Porteous, W.K.; Ledgerwood, E.C.; Smith, R.A.; Murphy, M.P. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem., 2001, 276 (7), 4588-4596.
288. Tomiyama, T.; Matsuyama, S.; Iso, H.; Umeda, T.; Takuma, H.; Ohnishi, K.; Ishibashi, K.; Teraoka, R.; Sakama, N.; Yamashita, T.; Nishitsuji, K.; Ito, K.; Shimada, H.; Lambert, M.P.; Klein, W.L.; Mori, H. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci,. 2010, 30 (14), 4845-4856.
289. Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science., 2002, 298 (5594), 789-791.
290. Oddo, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; La-Ferla, F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron., 2003, 39 (3), 409-421.
291. Jacobsen, J.S.; Wu, C.C.; Redwine, J.M.; Comery, T.A.; Arias, R.; Bowlby, M.; Martone, R.; Morrison, J.H.; Pangalos, M.N.; Reinhart, P.H.; Bloom, F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U S A, 2006, 103 (13), 5161-5166.
292. Haass, C.; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol., 2007, 8 (2), 101-112.
293. Ma, T.; Hoeffer, C.A.; Wong, H.; Massaad, C.A.; Zhou, P.; Iadecola, C.; Murphy, M.P.; Pautler, R.G.; Klann, E. Amyloid betainduced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J. Neurosci., 2011, 31 (15), 5589-5595.
294. McManus, M.J.; Murphy, M.P.; Franklin, J.L. The mitochondriatargeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J. Neurosci., 2011, 31 (44), 15703-15715.
295. Kelso, G.F.; Porteous, C.M.; Hughes, G.; Ledgerwood, E.C.; Gane, A.M.; Smith, R.A.; Murphy, M.P. Prevention of mitochondrial oxidative damage using targeted antioxidants. Ann. N. Y. Acad. Sci., 2002, 959, 263-274.
296. Manczak, M.; Mao, P.; Calkins, M.J.; Cornea, A.; Reddy, A.P.; Murphy, M.P.; Szeto, H.H.; Park, B.; Reddy, P.H. Mitochondriatargeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J. Alzheimers Dis., 2010, 20 Suppl 2, S609-631.
297. Wani, W.Y.; Gudup, S.; Sunkaria, A.; Bal, A.; Singh, P.P.; Kandimalla, R.J.; Sharma, D.R.; Gill, K.D. Protective efficacy of mitochondrial targeted antioxidant MitoQ against dichlorvos induced oxidative stress and cell death in rat brain. Neuropharmacology., 2011, 61 (8), 1193-1201.
298. Neuzil, J.; Widen, C.; Gellert, N.; Swettenham, E.; Zobalova, R.; Dong, L.F.; Wang, X.F.; Lidebjer, C.; Dalen, H.; Headrick, J.P.; Witting, P.K. Mitochondria transmit apoptosis signalling in cardiomyocyte-like cells and isolated hearts exposed to experimental ischemia-reperfusion injury. Redox Rep., 2007, 12 (3), 148-162.
299. Chaturvedi, R.K.; Beal, M.F. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol. Cell. Neurosci., 2013, 55, 101-14.
300. Chaturvedi, R.K.; Calingasan, N.Y.; Yang, L.; Hennessey, T.; Johri, A.; Beal, M.F. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum. Mol. Genet., 2010, 19 (16), 3190-3205.
301. Chaturvedi, R.K.; Adhihetty, P.; Shukla, S.; Hennessy, T.; Calingasan, N.; Yang, L.; Starkov, A.; Kiaei, M.; Cannella, M.; Sassone, J.; Ciammola, A.; Squitieri, F.; Beal, M.F. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet., 2009, 18 (16), 3048-3065.
302. Chaturvedi, R.K.; Hennessey, T.; Johri, A.; Tiwari, S.K.; Mishra, D.; Agarwal, S.; Kim, Y.S.; Beal, M.F. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease. Hum. Mol. Genet., 2012, 21 (15), 3474-3488.
303. Eriksdotter-Jonhagen, M.; Linderoth, B.; Lind, G.; Aladellie, L.; Almkvist, O.; Andreasen, N.; Blennow, K.; Bogdanovic, N.; Jelic, V.; Kadir, A.; Nordberg, A.; Sundstrom, E.; Wahlund, L.O.; Wall, A.; Wiberg, M.; Winblad, B.; Seiger, A.; Almqvist, P.; Wahlberg, L. Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2012, 33 (1), 18-28.
304. Ichim, G.; Tauszig-Delamasure, S.; Mehlen, P. Neurotrophins and cell death. Exp. Cell Res., 2012, 318 (11), 1221-1228.
305. Chaturvedi, R.K.; Beal, M.F. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol. Cell. Neurosci., 2013, 55, 101-114.
306. Mao, P.; Manczak, M.; Calkins, M.J.; Truong, Q.; Reddy, T.P.; Reddy, A.P.; Shirendeb, U.; Lo, H.H.; Rabinovitch, P.S.; Reddy, P.H. Mitochondria-targeted catalase reduces abnormal APP processing, amyloid beta production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension. Hum. Mol. Genet., 2012, 21 (13), 2973-2990.
307. Popiel, H.A.; Nagai, Y.; Fujikake, N.; Toda, T. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamineinduced neurodegeneration in vivo. Mol. Ther., 2007, 15 (2), 303-309.